Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SM-88 in metastatic breast cancer
NCT02562612Phase 2Withdrawn
- Sponsor
- Tyme Technologies
- Start
- Oct 2022
- Primary completion
- Oct 2023
- Modality
- Small Molecules
01
Overview
Phase 2, open-label, single-arm trial of racemetyrosine in breast cancer, sponsored by Tyme Technologies. Primary endpoints: Response Rate and Progression-Free Survival. Planned start Oct 2022; status: withdrawn.
02
Drugs
racemetyrosine
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT02562612.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02562612.